Abstract:Choroidal neovascularization (CNV) is one of the severe pathological consequences of the end-stage of age-related macular degeneration (AMD). Several lines of evidence implicate increased levels of vascular endothelial growth factor (VEGF) in the retinas of AMD patients. Current available agents for the inhibition of VEGF protein such as bevacizumab show significant promise for the treatment of exudative AMD. However, this compound still has limited efficacy and requires multiple administrations; thus, it is associated with a variety of ocular complications, including endophthalmitis and retinal detachment. In this study, we used anti-VEGFA/VEGFR2 or non-specific siRNA and evaluated their suppression of laser-induced choroidal neovascularization (CNV) in mice. Male adult C57BL/6J mice were used in the study. The mice were subjected to laser rupture of Bruch's membrane to induce CNV and then randomized to five groups with six mice per group. The five groups were blank control, vehicle control (5% glucose solution, GS), VEGFA.siRNA, VEGFR2.siRNA, and non-specific siRNA. Two days after laser photocoagulation, each group, with the exception of the blank control group, received 1 microl of the appropriate agent by intravitreal injection to both eyes. Seven days later, after taking fundus photography and fundus fluorescein angiography (FFA), the mice were killed for tissue sampling. Six eyes from three mice in each group were used for choroidal flatmounts to examine CNV. Six eyes from three mice in each group were subjected to RNA extraction for VEGF mRNA quantification by qRT-PCR. Retinal tissue from 2 mice without laser treatment was harvested as the assay reference. The incidence of burns which showed fluorescein leakage was 80.0% in blank control, 75.0% in GS, 55.0% in VEGFA.siRNA, 40.0% in VEGFR2.siRNA and 30.0% in non-specific siRNA group. The flatmounted specimens showed that the retinal pigment epithelium (RPE) was visualized as a uniform hexagonal array in nonlasered areas. On day 7 after laser burn, well-defined isolectin-B4 labeled CNV networks were shown within the burn spots of the 2 control groups. The inhibitory effects of the 3 siRNAs on CNV formation were statistically significant as compared to the 2 control groups. Compared to the control groups, the ocular expression of VEGF mRNA was decreased significantly in the 3 siRNA treated groups. The areas of CNV correlated with the expression of VEGF mRNA. Anti-VEGFA/VEGFR2 or non-specific siRNA can inhibit CNV and attenuate VEGF mRNA expression in a laser-induced mouse model of CNV. We conclude that the siRNAs may be an option for treating patients with exudative AMD, and more studies are needed to test the possible side-effects of the treatment.

Combination Of Targeted Pdt And Anti-Vegf Therapy For Rat Cnv By Rgd-Modified Liposomal Photocyanine And Sorafenib

A Synergistic Therapy with Antioxidant and Anti‐VEGF: Towards Its Safe and Effective Elimination for Corneal Neovascularization

A Synergistic Therapy with Antioxidant and Anti-VEGF: Toward Its Safe and Effective Elimination for Corneal Neovascularization

Intravenous anti-VEGF agents with RGD peptide-targeted core cross-linked star (CCS) polymers modified with indocyanine green for imaging and treatment of laser-induced choroidal neovascularization

A Lipid Nanoparticle System Improves Sirna Efficacy in Rpe Cells and A Laser-Induced Murine Cnv Model

Light‐Activated Anti‐Vascular Combination Therapy against Choroidal Neovascularization

EphA2 Targeted Doxorubicin Stealth Liposomes As a Therapy System for Choroidal Neovascularization in Rats

Topical ocular delivery to laser-induced choroidal neovascularization by dual internalizing RGD and TAT peptide-modified nanoparticles

C176-loaded and Phosphatidylserine-Modified Nanoparticles Treat Retinal Neovascularization by Promoting M2 Macrophage Polarization

Targeted Treatment of Choroidal Neovascularization Using Integrin-Mediated Sterically Stabilized Liposomes Loaded with Combretastatin A4

Effect of octreotide combined with transpupillary thermotherapy on experimental choroidal neovascularization

Targeted Long-term Noninvasive Treatment of Choroidal Neovascularization by Biodegradable Nanoparticles

Topical Application of Cell-Penetrating Peptide Modified Anti-VEGF Drug Alleviated Choroidal Neovascularization in Mice

Targeted Noninvasive Treatment of Choroidal Neovascularization by Hybrid Cell-Membrane-Cloaked Biomimetic Nanoparticles

Biomimetic Nanocomplex Based Corneal Neovascularization Theranostics.

Octreotide Inhibits Choroidal Neovascularization in Rats

Cyclic RGD Peptide Targeting Coated Nano Drug Co-Delivery System for Therapeutic Use in Age-Related Macular Degeneration Disease

The Effect of CM082, an Oral Tyrosine Kinase Inhibitor, on Experimental Choroidal Neovascularization in Rats

Targeted 8-arm PEG Nanosystems for Localization of Choroidal Neovascularization Macular Degeneration Model

In Vivo Assembly Drug Delivery Strategy Based on Ultra-Small Nanoparticles: Toward High Drug Permeation and Accumulation for Cnv Treatment

Inhibition of experimental choroidal neovascularization in mice by anti-VEGFA/VEGFR2 or non-specific siRNA